Previous close | 13.69 |
Open | 13.82 |
Bid | 14.16 x 200 |
Ask | 14.23 x 100 |
Day's range | 13.82 - 14.71 |
52-week range | 10.92 - 59.99 |
Volume | |
Avg. volume | 1,057,254 |
Market cap | 853.381M |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Investors in Sage Therapeutics, Inc. ( NASDAQ:SAGE ) had a good week, as its shares rose 2.7% to close at US$13.69...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Sage Therapeutics ( NASDAQ:SAGE ) First Quarter 2024 Results Key Financial Results Revenue: US$7.90m (up 140% from 1Q...